Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients ; volume:3 ; number:1 ; day:21 ; month:5 ; year:2024 ; pages:1-12 ; date:12.2024
Holistic integrative oncology ; 3, Heft 1 (21.5.2024), 1-12, 12.2024
- Creator
-
Hao, Yiping
Ji, Min
Jin, Shumin
Li, Wei
Zhou, Ying
Jia, Ruinan
Li, Wěi
Jiang, Huihui
Wang, Jingtao
Lu, Fei
Zang, Shaolei
Zhang, Chunqing
Ye, Jingjing
Ji, Chunyan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s44178-024-00088-7
- URN
-
urn:nbn:de:101:1-2407292125292.286670234005
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hao, Yiping
- Ji, Min
- Jin, Shumin
- Li, Wei
- Zhou, Ying
- Jia, Ruinan
- Li, Wěi
- Jiang, Huihui
- Wang, Jingtao
- Lu, Fei
- Zang, Shaolei
- Zhang, Chunqing
- Ye, Jingjing
- Ji, Chunyan
- SpringerLink (Online service)
Other Objects (12)
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
![Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
AML consolidation therapy: timing matters
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Optimal Post-Remission Consolidation Therapy in Patients with AML
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine